Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Investigational triple agonist acting at the GLP-1, GIP, and glucagon receptors
GLP-1 users saw a 44% reduction in hospitalizations due to stroke, heart attack and heart failure compared to the control group
Because of its Triple G action, users have reported that retatrutide is able to burn fat without the extreme appetite suppression associated with without semaglutide or tirzepatide
Many patients receive compounded GLP-1 medications in vials and feel unsure about injecting at home
Author: Alex Montero, Grace Sparks, Marley Presiado, and Liz Hamel
US$ 24.43
US$ 26.71
US$ 24.96
US$ 28.85
US$ 23.49
US$ 20.79
US$ 21.68
